

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM722335

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	SECURITY INTEREST		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
BIOXCEL THERAPEUTICS, INC.		04/19/2022	Corporation: DELAWARE
RECEIVING PARTY DATA			
Name:	Oaktree Fund Administration, LLC		
Street Address:	333 S. Grand Avenue, 28th Fl.		
City:	Los Angeles		
State/Country:	CALIFORNIA		
Postal Code:	90071		
Entity Type:	Limited Liability Company: DELAWARE		
PROPERTY NUMBERS Total: 9			
Property Type	Number	Word Mark	
Serial Number:	90295385	ALMIQI	
Serial Number:	88910081	BT	
Registration Number:	6359361	BT BIOXCEL THERAPEUTICS	
Serial Number:	90321408		
Serial Number:	90295383	IGALMI	
Serial Number:	88694201	KALMPEN	
Serial Number:	97021170	OMFILTO	
Serial Number:	97021169	RELFINBI	
Serial Number:	97021171	ZELTIGNA	
CORRESPONDENCE DATA			
Fax Number:	2029567069		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
Phone:	2029567685		
Email:	carrierr@sullcrom.com, nguyenb@sullcrom.com		
Correspondent Name:	Rita M. Carrier		
Address Line 1:	1700 New York Avenue, N.W., Suite 700		
Address Line 2:	Sullivan & Cromwell LLP		
Address Line 4:	Washington, D.C. 20006-5215		

OP \$240.00 90295385

ATTORNEY DOCKET NUMBER:	018392.00094 CA (RMC)
NAME OF SUBMITTER:	RITA M. CARRIER
SIGNATURE:	/RITA M. CARRIER/
DATE SIGNED:	04/19/2022

Total Attachments: 15

source=BioXcel - Trademark Security Agreement (Credit Agreement)#page1.tif
source=BioXcel - Trademark Security Agreement (Credit Agreement)#page2.tif
source=BioXcel - Trademark Security Agreement (Credit Agreement)#page3.tif
source=BioXcel - Trademark Security Agreement (Credit Agreement)#page4.tif
source=BioXcel - Trademark Security Agreement (Credit Agreement)#page5.tif
source=BioXcel - Trademark Security Agreement (Credit Agreement)#page6.tif
source=BioXcel - Trademark Security Agreement (Credit Agreement)#page7.tif
source=BioXcel - Trademark Security Agreement (Credit Agreement)#page8.tif
source=BioXcel - Trademark Security Agreement (Credit Agreement)#page9.tif
source=BioXcel - Trademark Security Agreement (Credit Agreement)#page10.tif
source=BioXcel - Trademark Security Agreement (Credit Agreement)#page11.tif
source=BioXcel - Trademark Security Agreement (Credit Agreement)#page12.tif
source=BioXcel - Trademark Security Agreement (Credit Agreement)#page13.tif
source=BioXcel - Trademark Security Agreement (Credit Agreement)#page14.tif
source=BioXcel - Trademark Security Agreement (Credit Agreement)#page15.tif

TRADEMARK SECURITY AGREEMENT

This TRADEMARK SECURITY AGREEMENT, dated as of April 19, 2022 (“*Trademark Security Agreement*”), made by each of the signatories hereto (the “*Trademark Grantors*”), is in favor of Oaktree Fund Administration, LLC, as administrative agent for the Secured Parties (in such capacity, together with its successors and assigns, the “*Administrative Agent*”).

W I T N E S S E T H:

WHEREAS, the Trademark Grantors are party to a Security Agreement, dated as April 19, 2022 (the “*Security Agreement*”) in favor of the Administrative Agent, pursuant to which the Trademark Grantors are required to execute and deliver this Trademark Security Agreement (capitalized terms used but not otherwise defined herein shall have the meanings given to them in the Security Agreement);

WHEREAS, pursuant to the terms of the Security Agreement, each Trademark Grantor has created in favor of the Administrative Agent a security interest in, and the Administrative Agent has become a secured creditor with respect to, the Trademark Collateral (as defined below);

NOW, THEREFORE, in consideration of the premises and to induce the Administrative Agent and the Lender to enter into the Credit Agreement and to induce the Lender to make their respective extensions of credit to the Borrower thereunder, each Trademark Grantor hereby grants to the Administrative Agent, for itself and on behalf of and for the ratable benefit of the other Secured Parties, a security interest in all of the following property now owned or at any time hereafter acquired by such Trademark Grantor or in which such Trademark Grantor now has or at any time in the future may acquire any right, title or interest (collectively, the “*Trademark Collateral*”), as collateral security for the complete payment and performance when due (whether at the stated maturity, by acceleration or otherwise) of all Secured Obligations:

(a) all Trademarks of such Trademark Grantor, including, without limitation, the registered and applied-for Trademarks of such Trademark Grantor listed on **Schedule 1** attached hereto; provided, that no Lien or security interest is granted hereunder with respect to any United States “intent-to-use” trademark or service mark application filed pursuant to Section 1(b) of the Lanham Act, solely to the extent that, and only for so long as, the grant of a security interest therein would impair the validity or enforceability of, or render void or voidable or result in the cancellation of, any Trademark Grantor’s right, title or interest therein;

(b) to the extent not covered by **clause (a)**, all income, royalties and other payments now or hereafter due and payable with respect to any of the foregoing;

(c) to the extent not covered by **clause (a)**, the goodwill of the businesses which the Trademarks are associated with and symbolize; and

(d) to the extent not covered by **clause (a)**, all causes of action arising prior to or after the date hereof for infringement, dilution or other violation of any of the Trademarks or

unfair competition regarding the same, together with the right to seek and retain any past or future damages in connection therewith.

The security interest granted pursuant to this Trademark Security Agreement is granted in conjunction with the security interest granted to the Administrative Agent pursuant to the Security Agreement, and the Trademark Grantors hereby acknowledge and affirm that the rights and remedies of the Administrative Agent with respect to the security interest in the Trademarks made and granted hereby are more fully set forth in the Security Agreement. In the event that any provision of this Trademark Security Agreement is deemed to conflict with the Security Agreement, the provisions of the Security Agreement shall govern.

Each Trademark Grantor hereby authorizes and requests that the Commissioner of Trademarks record this Trademark Security Agreement.

THIS TRADEMARK SECURITY AGREEMENT AND THE RIGHTS AND OBLIGATIONS OF THE PARTIES UNDER THIS TRADEMARK SECURITY AGREEMENT SHALL BE GOVERNED BY, AND CONSTRUED AND INTERPRETED IN ACCORDANCE WITH, THE LAW OF THE STATE OF NEW YORK.

This Trademark Security Agreement may be executed by one or more of the parties to this Trademark Security Agreement on any number of separate counterparts, and all of said counterparts taken together shall be deemed to constitute one and the same instrument. Delivery of an executed signature page of this Trademark Security Agreement by facsimile transmission or electronic transmission (in PDF format) shall be effective as delivery of a manually executed counterpart hereof.

[Remainder of This Page Intentionally Left Blank.]

IN WITNESS WHEREOF, the Grantor has caused this TRADEMARK SECURITY AGREEMENT to be executed and delivered by its duly authorized officer as of the date first above written.

BIOXCEL THERAPEUTICS, INC.

By: Vimal Mehta
Name: Vimal Mehta
Title: Chief Executive Officer

Address: 555 Long Wharf Drive, 12th Floor
New Haven, CT
06511


A copy (which shall not constitute notice) shall also be sent to:

Cooley LLP
3 Embarcadero Center
20th Floor
San Francisco, CA 94111-4004
Attn: Mischi a Marca
Email: gmamarca@cooley.com

ADMINISTRATIVE AGENT:



OAKTREE FUND ADMINISTRATION, LLC


By: Oaktree Capital Management, L.P.
Its: Managing Member


By: 
Name: Jessica Dombroff
Title: Vice President


By: 
Name: Kendall Bass
Title: Vice President


BioXcel Therapeutics, Inc.
Trademark Filings


MARK	COUNTRY	APPLICATION/REGISTRATION NO.	GOODS/SERVICES
ALMIQI	United States	Application No. 90295385	Class 05: Pharmaceutical for the treatment of agitation; pharmaceuticals for the treatment of agitation associated with neuropsychiatric conditions, neurodegenerative diseases, alcohol withdrawal, opioid use disorder, opioid withdrawal, substance abuse withdrawal, or other central nervous system disorders Class 05: Pharmaceutical preparations in the field of immuno-oncology; pharmaceutical preparations for the treatment of neurological conditions
BT (Stylized) 	United States	Application No. 88910081	First Use: May-31-2017 / First Use in Commerce: May-31-2017 Class 42: Pharmaceutical research and development in the fields of neuroscience and immuno-oncology First Use: May-31-2017 / First Use in Commerce: May-31-2017
BT BIOXCEL THERAPEUTICS	United States	Application No. 88885185 Registration No. 6359361	Class 05: Pharmaceutical preparations in the field of immuno-oncology; pharmaceutical preparations for the treatment of neurological conditions First Use: Mar-31-2017 / First Use in Commerce: Mar-31-2017 Class 42: Pharmaceutical research and development in the fields of neuroscience and immuno-oncology First Use: Mar-31-2017 / First Use in Commerce: Mar-31-2017
Horizontal Figure 8 Design 	United States	Application No. 90321408	Class 05: Pharmaceuticals for the treatment of agitation; pharmaceuticals for the treatment of agitation associated with neuropsychiatric conditions, neurodegenerative diseases, alcohol withdrawal, opioid use disorder, opioid withdrawal, substance abuse withdrawal, or other central nervous system disorders
IGALMI	United States	Application No. 90295383	Class 05: Pharmaceuticals for the treatment of agitation, namely, an orally-dissolving formulation used for the treatment of agitation associated with alcohol withdrawal, opioid use disorder, opioid withdrawal, substance abuse withdrawal, or other central nervous system disorders, namely, schizophrenia, bipolar disorder, dementia, and depression
KALMPEN	United States	Application No. 88694201	Class 05: Injectable pharmaceuticals for the treatment of agitation; injectable pharmaceuticals for the treatment of agitation associated with neuropsychiatric conditions, neurodegenerative diseases, alcohol withdrawal, opioid use disorder, opioid withdrawal, substance abuse withdrawal and other related central nervous system disorders
OMFILTO	United States	Application No. 97021170	Class 05: Pharmaceuticals for the treatment of central nervous system disorders; pharmaceuticals for the treatment of neurological and psychiatric disorders; pharmaceuticals for the treatment of agitation; pharmaceuticals for the treatment of agitation associated with neuropsychiatric conditions, neurodegenerative diseases, schizophrenia, bipolar disorder, dementia, delirium, alcohol withdrawal, opioid use disorder, opioid withdrawal, substance abuse withdrawal, depression or any other central nervous system disorder; pharmaceuticals for the treatment of symptoms associated with alcohol withdrawal, opioid use disorder, opioid withdrawal, substance abuse withdrawal, depression or other central nervous system disorders


MARK	COUNTRY	APPLICATION/ REGISTRATION NO.	GOODS/SERVICES
RELFINBI	United States	Application No. 97021169	Class 05: Pharmaceuticals for the treatment of central nervous system disorders; pharmaceuticals for the treatment of neurological and psychiatric disorders; pharmaceuticals for the treatment of agitation; pharmaceuticals for the treatment of agitation associated with neuro-psychiatric conditions; neurodegenerative diseases; schizophrenia, bipolar disorder, dementia, delirium, alcohol withdrawal, opioid use disorder, opioid withdrawal, substance abuse withdrawal, depression or any other central nervous system disorder; pharmaceuticals for the treatment of symptoms associated with alcohol withdrawal, opioid use disorder, opioid withdrawal, substance abuse withdrawal, depression or other central nervous system disorders
ZELTIGNA	United States	Application No. 97021171	Class 05: Pharmaceuticals for the treatment of central nervous system disorders; pharmaceuticals for the treatment of neurological and psychiatric disorders; pharmaceuticals for the treatment of agitation; pharmaceuticals for the treatment of agitation associated with neuro-psychiatric conditions; neurodegenerative diseases; schizophrenia, bipolar disorder, dementia, delirium, alcohol withdrawal, opioid use disorder, opioid withdrawal, substance abuse withdrawal, depression or any other central nervous system disorder; pharmaceuticals for the treatment of symptoms associated with alcohol withdrawal, opioid use disorder, opioid withdrawal, substance abuse withdrawal, depression or other central nervous system disorders
ALMIQI	Australia (via Madrid Protocol)	Application No. 2185567 Registration No. 1595882	Class 05: Pharmaceuticals for the treatment of agitation; pharmaceuticals for the treatment of agitation associated with neuro-psychiatric conditions; neurodegenerative diseases; alcohol withdrawal, opioid use disorder, opioid withdrawal, substance abuse withdrawal, or other central nervous system disorders
Horizontal Figure 8 Design 	Australia (via Madrid Protocol)	Application No. 2198143 Registration No. 1603962	Class 05: Pharmaceuticals for the treatment of agitation; pharmaceuticals for the treatment of agitation associated with neuro-psychiatric conditions; neurodegenerative diseases; alcohol withdrawal, opioid use disorder, opioid withdrawal, substance abuse withdrawal, or other central nervous system disorders
IGALMI	Australia (via Madrid Protocol)	Application No. 2185561 Registration No. 1595905	Class 05: Pharmaceuticals for the treatment of agitation; pharmaceuticals for the treatment of agitation associated with neuro-psychiatric conditions; neurodegenerative diseases; alcohol withdrawal, opioid use disorder, opioid withdrawal, substance abuse withdrawal, or other central nervous system disorders
OMFLTO	Australia (via Madrid Protocol)	Application No. A0120401	Class 05: Pharmaceuticals for the treatment of central nervous system disorders; pharmaceuticals for the treatment of neurological and psychiatric disorders; pharmaceuticals for the treatment of agitation; pharmaceuticals for the treatment of agitation associated with neuro-psychiatric conditions; neurodegenerative diseases; schizophrenia, bipolar disorder, dementia, delirium, alcohol withdrawal, opioid use disorder, opioid withdrawal, substance abuse withdrawal, depression or any other central nervous system disorder; pharmaceuticals for the treatment of symptoms associated with alcohol withdrawal, opioid use disorder, opioid withdrawal, substance abuse withdrawal, depression or other central nervous system disorders

MARK	COUNTRY	APPLICATION/ REGISTRATION NO.	GOODS/SERVICES
RELFINBI	Australia (via Madrid Protocol)	Application No. A01203399	Class 05: Pharmaceuticals for the treatment of central nervous system disorders; pharmaceuticals for the treatment of neurological and psychiatric disorders; pharmaceuticals for the treatment of agitation; pharmaceuticals for the treatment of agitation associated with neuro-psychiatric conditions; neurodegenerative diseases; schizophrenia; bipolar disorder; dementia; delirium; alcohol withdrawal; opioid use disorder; opioid withdrawal; substance abuse withdrawal; depression or any other central nervous system disorder; pharmaceuticals for the treatment of symptoms associated with alcohol withdrawal; opioid use disorder; opioid withdrawal; substance abuse withdrawal; depression or other central nervous system disorders
ZELTIGNA	Australia (via Madrid Protocol)	Application No. A01203398	Class 05: Pharmaceuticals for the treatment of central nervous system disorders; pharmaceuticals for the treatment of neurological and psychiatric disorders; pharmaceuticals for the treatment of agitation; pharmaceuticals for the treatment of agitation associated with neuro-psychiatric conditions; neurodegenerative diseases; schizophrenia; bipolar disorder; dementia; delirium; alcohol withdrawal; opioid use disorder; opioid withdrawal; substance abuse withdrawal; depression or any other central nervous system disorder; pharmaceuticals for the treatment of symptoms associated with alcohol withdrawal; opioid use disorder; opioid withdrawal; substance abuse withdrawal; depression or other central nervous system disorders
ALMIQI	Canada (via Madrid Protocol)	Application No. 2113252	Class 05: Pharmaceuticals for the treatment of agitation; pharmaceuticals for the treatment of agitation associated with neuro-psychiatric conditions; neurodegenerative diseases; alcohol withdrawal; opioid use disorder; opioid withdrawal; substance abuse withdrawal; or other central nervous system disorders
BT (Stylized)	Canada	Application No. 2058408	Class 05: Pharmaceutical preparations in the field of immuno-oncology; pharmaceutical preparations for the treatment of neurological conditions Class 42: Pharmaceutical research and development in the fields of neuroscience and immuno-oncology
BT BIONXCEL THERAPEUTICS	Canada	Application No. 2058401	Class 05: Pharmaceutical preparations in the field of immuno-oncology; pharmaceutical preparations for the treatment of neurological conditions Class 42: Pharmaceutical research and development in the fields of neuroscience and immuno-oncology
Horizontal Figure 8 Design 	Canada (via Madrid Protocol)	Application No. 2123736	Class 05: Pharmaceuticals for the treatment of agitation; pharmaceuticals for the treatment of agitation associated with neuro-psychiatric conditions; neurodegenerative diseases; alcohol withdrawal; opioid use disorder; opioid withdrawal; substance abuse withdrawal; or other central nervous system disorders
IGALMI	Canada (via Madrid Protocol)	Application No. 2113251	Class 05: Pharmaceuticals for the treatment of agitation; pharmaceuticals for the treatment of agitation associated with neuro-psychiatric conditions; neurodegenerative diseases; alcohol withdrawal; opioid use disorder; opioid withdrawal; substance abuse withdrawal; or other central nervous system disorders
KALMPEN	Canada	Application No. 2028439	Class 05: Injectable pharmaceuticals for the treatment of agitation; injectable pharmaceuticals for the treatment of agitation associated with neuro-psychiatric conditions; neurodegenerative diseases; alcohol withdrawal; opioid use disorder; opioid withdrawal; substance abuse withdrawal; or other related central nervous system disorders



MARK	COUNTRY	APPLICATION/ REGISTRATION NO.	GOODS/SERVICES
OMFLITO	Canada (via Madrid Protocol)	Application No. A0120401	Class 05: Pharmaceuticals for the treatment of central nervous system disorders; pharmaceuticals for the treatment of neurological and psychiatric disorders; pharmaceuticals for the treatment of agitation; pharmaceuticals for the treatment of agitation associated with neuro-psychiatric conditions; neurodegenerative diseases; schizophrenia, bipolar disorder, dementia, delirium, alcohol withdrawal, opioid use disorder; opioid withdrawal, substance abuse withdrawal, depression or any other central nervous system disorder; pharmaceuticals for the treatment of symptoms associated with alcohol withdrawal, opioid use disorder; opioid withdrawal, substance abuse withdrawal, depression or other central nervous system disorders
PACIFLM	Canada	Application No. 2034474	Class 05: Pharmaceuticals for the treatment of agitation; pharmaceuticals for the treatment of agitation associated with neuro-psychiatric conditions; neurodegenerative diseases; alcohol withdrawal, opioid use disorder; opioid withdrawal, substance abuse withdrawal, or other central nervous system disorders
PACIPEN	Canada (via Madrid Protocol)	Application No. 2091084	Class 05: Injectable pharmaceutical preparations for the treatment of agitation; injectable pharmaceutical preparations for the treatment of agitation associated with neuro-psychiatric conditions; neurodegenerative diseases; alcohol withdrawal, opioid use disorder; opioid withdrawal, substance abuse withdrawal and other related central nervous system disorders
RELFINBI	Canada (via Madrid Protocol)	Application No. A0120399	Class 05: Pharmaceuticals for the treatment of central nervous system disorders; pharmaceuticals for the treatment of neurological and psychiatric disorders; pharmaceuticals for the treatment of agitation; pharmaceuticals for the treatment of agitation associated with neuro-psychiatric conditions; neurodegenerative diseases; schizophrenia, bipolar disorder, dementia, delirium, alcohol withdrawal, opioid use disorder; opioid withdrawal, substance abuse withdrawal, depression or any other central nervous system disorder; pharmaceuticals for the treatment of symptoms associated with alcohol withdrawal, opioid use disorder; opioid withdrawal, substance abuse withdrawal, depression or other central nervous system disorders
ZELTIGNA	Canada (via Madrid Protocol)	Application No. A0120398	Class 05: Pharmaceuticals for the treatment of central nervous system disorders; pharmaceuticals for the treatment of neurological and psychiatric disorders; pharmaceuticals for the treatment of agitation; pharmaceuticals for the treatment of agitation associated with neuro-psychiatric conditions; neurodegenerative diseases; schizophrenia, bipolar disorder, dementia, delirium, alcohol withdrawal, opioid use disorder; opioid withdrawal, substance abuse withdrawal, depression or any other central nervous system disorder; pharmaceuticals for the treatment of symptoms associated with alcohol withdrawal, opioid use disorder; opioid withdrawal, substance abuse withdrawal, depression or other central nervous system disorders
ALMIOI	European Union (via Madrid Protocol)	Application No. 1595882 Registration No. 1595882	Class 05: Pharmaceuticals for the treatment of agitation; pharmaceuticals for the treatment of agitation associated with neuro-psychiatric conditions; neurodegenerative diseases; alcohol withdrawal, opioid use disorder; opioid withdrawal, substance abuse withdrawal, or other central nervous system disorders
BT (Stylized) 	European Union	Application No. 18322411 Registration No. 18322411	Class 05: Pharmaceutical preparations in the field of immuno-oncology; pharmaceutical preparations for the treatment of neurological conditions Class 42: Pharmaceutical research and development in the fields of neuroscience and immuno-oncology


MARK	COUNTRY	APPLICATION/ REGISTRATION NO.	GOODS/SERVICES
BT BIXOCEL THERAPEUTICS	European Union	Application No. 18322410 Registration No. 18322410	Class 05: Pharmaceutical preparations in the field of immuno-oncology; pharmaceutical preparations for the treatment of neurological conditions Class 42: Pharmaceutical research and development in the fields of neuroscience and immuno-oncology
Horizontal Figure 8 Design 	European Union (via Madrid Protocol)	Application No. 1603962 Registration No. 1603962	Class 05: Pharmaceuticals for the treatment of agitation; pharmaceuticals for the treatment of agitation associated with neuropsychiatric conditions, neurodegenerative diseases, alcohol withdrawal, opioid use disorder, opioid withdrawal, substance abuse withdrawal, or other central nervous system disorders
IGALMI	European Union (via Madrid Protocol)	Application No. 1595905 Registration No. 1595905	Class 05: Pharmaceuticals for the treatment of agitation; pharmaceuticals for the treatment of agitation associated with neuropsychiatric conditions, neurodegenerative diseases, alcohol withdrawal, opioid use disorder, opioid withdrawal, substance abuse withdrawal, or other central nervous system disorders
KALMPEN	European Union	Application No. 018239362 Registration No. 018239362	Class 05: Injectable pharmaceuticals for the treatment of agitation, injectable pharmaceuticals for the treatment of agitation associated with neuropsychiatric conditions, neurodegenerative diseases, alcohol withdrawal, opioid use disorder, opioid withdrawal, substance abuse withdrawal and other related central nervous system disorders.
OMFILTTO	European Union (via Madrid Protocol)	Application No. A0120401	Class 05: Pharmaceuticals for the treatment of central nervous system disorders; pharmaceuticals for the treatment of neurological and psychiatric disorders; pharmaceuticals for the treatment of agitation; pharmaceuticals for the treatment of agitation associated with neuropsychiatric conditions, neurodegenerative diseases, schizophrenia, bipolar disorder, dementia, delirium, alcohol withdrawal, opioid use disorder, opioid withdrawal, substance abuse withdrawal, depression or any other central nervous system disorder; pharmaceuticals for the treatment of symptoms associated with alcohol withdrawal, opioid use disorder, opioid withdrawal, substance abuse withdrawal, depression or other central nervous system disorders
PACIFILM	European Union	Application No. 18256423 Registration No. 18256423	Class 05: Pharmaceuticals for the treatment of agitation; pharmaceuticals for the treatment of agitation associated with neuropsychiatric conditions, neurodegenerative diseases, alcohol withdrawal, opioid use disorder, opioid withdrawal, substance abuse withdrawal, or other central nervous system disorders
PACIPEN	European Union (via Madrid Protocol)	Application No. 1580863	Class 05: Injectable pharmaceutical preparations for the treatment of agitation, injectable pharmaceutical preparations for the treatment of agitation associated with neuropsychiatric conditions, neurodegenerative diseases, alcohol withdrawal, opioid use disorder, opioid withdrawal, substance abuse withdrawal and other related central nervous system disorders

MARK	COUNTRY	APPLICATION/ REGISTRATION NO.	GOODS/SERVICES
RELFINBI	European Union (via Madrid Protocol)	Application No. A0120399	Class 05: Pharmaceuticals for the treatment of central nervous system disorders; pharmaceuticals for the treatment of neurological and psychiatric disorders; pharmaceuticals for the treatment of agitation; pharmaceuticals for the treatment of agitation associated with neuropsychiatric conditions; neurodegenerative diseases, schizophrenia, bipolar disorder, dementia, delirium, alcohol withdrawal, opioid use disorder, opioid withdrawal, substance abuse withdrawal, depression or any other central nervous system disorder; pharmaceuticals for the treatment of symptoms associated with alcohol withdrawal, opioid use disorder, opioid withdrawal, substance abuse withdrawal, depression or other central nervous system disorders
ZELTIGNA	European Union (via Madrid Protocol)	Application No. A0120398	Class 05: Pharmaceuticals for the treatment of central nervous system disorders; pharmaceuticals for the treatment of neurological and psychiatric disorders; pharmaceuticals for the treatment of agitation; pharmaceuticals for the treatment of agitation associated with neuropsychiatric conditions; neurodegenerative diseases, schizophrenia, bipolar disorder, dementia, delirium, alcohol withdrawal, opioid use disorder, opioid withdrawal, substance abuse withdrawal, depression or any other central nervous system disorder; pharmaceuticals for the treatment of symptoms associated with alcohol withdrawal, opioid use disorder, opioid withdrawal, substance abuse withdrawal, depression or other central nervous system disorders
ALMIQI	Japan (via Madrid Protocol)	Application No. 1595882	Class 05: Pharmaceuticals for the treatment of agitation; pharmaceuticals for the treatment of agitation associated with neuropsychiatric conditions; neurodegenerative diseases, alcohol withdrawal, opioid use disorder, opioid withdrawal, substance abuse withdrawal, or other central nervous system disorders
Horizontal Figure 8 Design 	Japan (via Madrid Protocol)	Application No. 1603962	Class 05: Pharmaceuticals for the treatment of agitation; pharmaceuticals for the treatment of agitation associated with neuropsychiatric conditions; neurodegenerative diseases, alcohol withdrawal, opioid use disorder, opioid withdrawal, substance abuse withdrawal, or other central nervous system disorders
IGALMI	Japan (via Madrid Protocol)	Application No. 1595905	Class 05: Pharmaceuticals for the treatment of agitation; pharmaceuticals for the treatment of agitation associated with neuropsychiatric conditions; neurodegenerative diseases, alcohol withdrawal, opioid use disorder, opioid withdrawal, substance abuse withdrawal, or other central nervous system disorders
OMFLTO	Japan (via Madrid Protocol)	Application No. A0120401	Class 05: Pharmaceuticals for the treatment of central nervous system disorders; pharmaceuticals for the treatment of neurological and psychiatric disorders; pharmaceuticals for the treatment of agitation; pharmaceuticals for the treatment of agitation associated with neuropsychiatric conditions; neurodegenerative diseases, schizophrenia, bipolar disorder, dementia, delirium, alcohol withdrawal, opioid use disorder, opioid withdrawal, substance abuse withdrawal, depression or any other central nervous system disorder; pharmaceuticals for the treatment of symptoms associated with alcohol withdrawal, opioid use disorder, opioid withdrawal, substance abuse withdrawal, depression or other central nervous system disorders

MARK	COUNTRY	APPLICATION/ REGISTRATION NO.	GOODS/SERVICES
ELFINBI	Japan (via Madrid Protocol)	Application No. A01203399	Class 05: Pharmaceuticals for the treatment of central nervous system disorders; pharmaceuticals for the treatment of neurological and psychiatric disorders; pharmaceuticals for the treatment of agitation; pharmaceuticals for the treatment of agitation associated with neuro-psychiatric conditions; neurodegenerative diseases; schizophrenia, bipolar disorder, dementia, delirium, alcohol withdrawal, opioid use disorder, opioid withdrawal, substance abuse withdrawal, depression or any other central nervous system disorder; pharmaceuticals for the treatment of symptoms associated with alcohol withdrawal, opioid use disorder, opioid withdrawal, substance abuse withdrawal, depression or other central nervous system disorders
ZELTIGNA	Japan (via Madrid Protocol)	Application No. A01203398	Class 05: Pharmaceuticals for the treatment of central nervous system disorders; pharmaceuticals for the treatment of neurological and psychiatric disorders; pharmaceuticals for the treatment of agitation; pharmaceuticals for the treatment of agitation associated with neuro-psychiatric conditions; neurodegenerative diseases; schizophrenia, bipolar disorder, dementia, delirium, alcohol withdrawal, opioid use disorder, opioid withdrawal, substance abuse withdrawal, depression or any other central nervous system disorder; pharmaceuticals for the treatment of symptoms associated with alcohol withdrawal, opioid use disorder, opioid withdrawal, substance abuse withdrawal, depression or other central nervous system disorders
ALMIQI	Madrid Protocol Designated Jurisdictions Australia, Canada, European Union, Japan, Switzerland, and United Kingdom	Application No. 1595882 Registration No. 1595882	Class 05: Pharmaceuticals for the treatment of agitation; pharmaceuticals for the treatment of agitation associated with neuro-psychiatric conditions; neurodegenerative diseases; alcohol withdrawal, opioid use disorder, opioid withdrawal, substance abuse withdrawal, or other central nervous system disorders
Horizontal Figure 8 Design 	Madrid Protocol Designated Jurisdictions Australia, Canada, European Union, Japan, Switzerland, and United Kingdom	Application No. 16033962 Registration No. 16033962	Class 05: Pharmaceuticals for the treatment of agitation; pharmaceuticals for the treatment of agitation associated with neuro-psychiatric conditions; neurodegenerative diseases; alcohol withdrawal, opioid use disorder, opioid withdrawal, substance abuse withdrawal, or other central nervous system disorders
IGALMI	Madrid Protocol Designated Jurisdictions Australia, Canada, European Union, Japan, Switzerland, and United Kingdom	Application No. 1595905 Registration No. 1595905	Class 05: Pharmaceuticals for the treatment of agitation; pharmaceuticals for the treatment of agitation associated with neuro-psychiatric conditions; neurodegenerative diseases; alcohol withdrawal, opioid use disorder, opioid withdrawal, substance abuse withdrawal, or other central nervous system disorders

MARK	COUNTRY	APPLICATION/ REGISTRATION NO.	GOODS/SERVICES
OMFLUTO	Madrid Protocol Designated Jurisdictions Australia, Canada, European Union, Japan, Switzerland, and United Kingdom	Application No. A0120401	Class 05: Pharmaceuticals for the treatment of central nervous system disorders; pharmaceuticals for the treatment of neurological and psychiatric disorders; pharmaceuticals for the treatment of agitation; pharmaceuticals for the treatment of agitation associated with neuro-psychiatric conditions; neurodegenerative diseases; schizophrenia, bipolar disorder, dementia, delirium, alcohol withdrawal, opioid use disorder; opioid withdrawal, substance abuse withdrawal, depression or any other central nervous system disorder; pharmaceuticals for the treatment of symptoms associated with alcohol withdrawal, opioid use disorder; opioid withdrawal, substance abuse withdrawal, depression or other central nervous system disorders
PACPEN	Madrid Protocol Designated Jurisdictions Canada, European Union, and United Kingdom	Application No. 1580863 Registration No. 1580863	Class 05: Injectable pharmaceutical preparations for the treatment of agitation; injectable pharmaceutical preparations for the treatment of agitation associated with neuro-psychiatric conditions; neurodegenerative diseases; alcohol withdrawal, opioid use disorder; opioid withdrawal, substance abuse withdrawal and other related central nervous system disorders
RELFINBI	Madrid Protocol Designated Jurisdictions Australia, Canada, European Union, Japan, Switzerland, and United Kingdom	Application No. A0120399	Class 05: Pharmaceuticals for the treatment of central nervous system disorders; pharmaceuticals for the treatment of neurological and psychiatric disorders; pharmaceuticals for the treatment of agitation; pharmaceuticals for the treatment of agitation associated with neuro-psychiatric conditions; neurodegenerative diseases; schizophrenia, bipolar disorder, dementia, delirium, alcohol withdrawal, opioid use disorder; opioid withdrawal, substance abuse withdrawal, depression or any other central nervous system disorder; pharmaceuticals for the treatment of symptoms associated with alcohol withdrawal, opioid use disorder; opioid withdrawal, substance abuse withdrawal, depression or other central nervous system disorders
ZELTGNA	Madrid Protocol Designated Jurisdictions Australia, Canada, European Union, Japan, Switzerland, and United Kingdom	Application No. A0120398	Class 05: Pharmaceuticals for the treatment of central nervous system disorders; pharmaceuticals for the treatment of neurological and psychiatric disorders; pharmaceuticals for the treatment of agitation; pharmaceuticals for the treatment of agitation associated with neuro-psychiatric conditions; neurodegenerative diseases; schizophrenia, bipolar disorder, dementia, delirium, alcohol withdrawal, opioid use disorder; opioid withdrawal, substance abuse withdrawal, depression or any other central nervous system disorder; pharmaceuticals for the treatment of symptoms associated with alcohol withdrawal, opioid use disorder; opioid withdrawal, substance abuse withdrawal, depression or other central nervous system disorders
ALMIOI	Switzerland (via Madrid Protocol)	Application No. 1595882	Class 05: Pharmaceuticals for the treatment of agitation; pharmaceuticals for the treatment of agitation associated with neuro-psychiatric conditions; neurodegenerative diseases; alcohol withdrawal, opioid use disorder; opioid withdrawal, substance abuse withdrawal, or other central nervous system disorders

MARK	COUNTRY	APPLICATION/ REGISTRATION NO.	GOODS/SERVICES
Horizontal Figure 8 Design 	Switzerland (via Madrid Protocol)	Application No. 1603962	Class 05: Pharmaceuticals for the treatment of agitation; pharmaceuticals for the treatment of agitation associated with neuropsychiatric conditions; neurodegenerative diseases; alcohol withdrawal; opioid use disorder; opioid withdrawal; substance abuse withdrawal, or other central nervous system disorders
IGALMI	Switzerland (via Madrid Protocol)	Application No. 1595905	Class 05: Pharmaceuticals for the treatment of agitation; pharmaceuticals for the treatment of agitation associated with neuropsychiatric conditions; neurodegenerative diseases; alcohol withdrawal; opioid use disorder; opioid withdrawal; substance abuse withdrawal, or other central nervous system disorders
OMFLTO	Switzerland (via Madrid Protocol)	Application No. A0120401	Class 05: Pharmaceuticals for the treatment of central nervous system disorders; pharmaceuticals for the treatment of neurological and psychiatric disorders; pharmaceuticals for the treatment of agitation; pharmaceuticals for the treatment of agitation associated with neuropsychiatric conditions; neurodegenerative diseases; schizophrenia; bipolar disorder; dementia; delirium; alcohol withdrawal; opioid use disorder; opioid withdrawal; substance abuse withdrawal; depression or any other central nervous system disorder; pharmaceuticals for the treatment of symptoms associated with alcohol withdrawal; opioid use disorder; opioid withdrawal; substance abuse withdrawal; depression or other central nervous system disorders
RELFNBI	Switzerland (via Madrid Protocol)	Application No. A0120399	Class 05: Pharmaceuticals for the treatment of central nervous system disorders; pharmaceuticals for the treatment of neurological and psychiatric disorders; pharmaceuticals for the treatment of agitation; pharmaceuticals for the treatment of agitation associated with neuropsychiatric conditions; neurodegenerative diseases; schizophrenia; bipolar disorder; dementia; delirium; alcohol withdrawal; opioid use disorder; opioid withdrawal; substance abuse withdrawal; depression or any other central nervous system disorder; pharmaceuticals for the treatment of symptoms associated with alcohol withdrawal; opioid use disorder; opioid withdrawal; substance abuse withdrawal; depression or other central nervous system disorders
ZELTGNA	Switzerland (via Madrid Protocol)	Application No. A0120398	Class 05: Pharmaceuticals for the treatment of central nervous system disorders; pharmaceuticals for the treatment of neurological and psychiatric disorders; pharmaceuticals for the treatment of agitation; pharmaceuticals for the treatment of agitation associated with neuropsychiatric conditions; neurodegenerative diseases; schizophrenia; bipolar disorder; dementia; delirium; alcohol withdrawal; opioid use disorder; opioid withdrawal; substance abuse withdrawal; depression or any other central nervous system disorder; pharmaceuticals for the treatment of symptoms associated with alcohol withdrawal; opioid use disorder; opioid withdrawal; substance abuse withdrawal; depression or other central nervous system disorders
ALMIQI	United Kingdom (via Madrid Protocol)	Application No. 1595882 Registration No. 1595882	Class 05: Pharmaceuticals for the treatment of agitation; pharmaceuticals for the treatment of agitation associated with neuropsychiatric conditions; neurodegenerative diseases; alcohol withdrawal; opioid use disorder; opioid withdrawal; substance abuse withdrawal, or other central nervous system disorders
BT (Stylized) 	United Kingdom	Application No. 3545498 Registration No. 3545498	Class 05: Pharmaceutical preparations in the field of immuno-oncology; pharmaceutical preparations for the treatment of neurological conditions Class 42: Pharmaceutical research and development in the fields of neuroscience and immuno-oncology

MARK	COUNTRY	APPLICATION/ REGISTRATION NO.	GOODS/SERVICES
BT BIXOCEL THERAPEUTICS	United Kingdom	Application No. 3545496 Registration No. 3545496	Class 05: Pharmaceutical preparations in the field of immuno-oncology; pharmaceutical preparations for the treatment of neurological conditions Class 42: Pharmaceutical research and development in the fields of neuroscience and immuno-oncology
	United Kingdom (via Madrid Protocol)	Application No. 1603962 Registration No. 1603962	Class 05: Pharmaceuticals for the treatment of agitation; pharmaceuticals for the treatment of agitation associated with neuropsychiatric conditions, neurodegenerative diseases; alcohol withdrawal, opioid use disorder, opioid withdrawal, substance abuse withdrawal, or other central nervous system disorders
IGALMI	United Kingdom (via Madrid Protocol)	Application No. 1595905 Registration No. 1595905	Class 05: Pharmaceuticals for the treatment of agitation; pharmaceuticals for the treatment of agitation associated with neuropsychiatric conditions, neurodegenerative diseases; alcohol withdrawal, opioid use disorder, opioid withdrawal, substance abuse withdrawal, or other central nervous system disorders
KALMPEN	United Kingdom	Application No. 3489749	Class 05: Injectable pharmaceuticals for the treatment of agitation; injectable pharmaceuticals for the treatment of agitation associated with neuropsychiatric conditions, neurodegenerative diseases; alcohol withdrawal, opioid use disorder; opioid withdrawal, substance abuse withdrawal and other related central nervous system disorders
KALMPEN	United Kingdom	Application No. 018239362 Registration No. UK00918239362	Class 05: Injectable pharmaceuticals for the treatment of agitation; injectable pharmaceuticals for the treatment of agitation associated with neuropsychiatric conditions, neurodegenerative diseases; alcohol withdrawal, opioid use disorder; opioid withdrawal, substance abuse withdrawal and other related central nervous system disorders.
OMFELTO	United Kingdom (via Madrid Protocol)	Application No. A0120401	Class 05: Pharmaceuticals for the treatment of central nervous system disorders; pharmaceuticals for the treatment of neurological and psychiatric disorders; pharmaceuticals for the treatment of agitation; pharmaceuticals for the treatment of agitation associated with neuropsychiatric conditions, neurodegenerative diseases; schizophrenia, bipolar disorder, dementia, delirium, alcohol withdrawal, opioid use disorder; opioid withdrawal, substance abuse withdrawal, depression or any other central nervous system disorder; pharmaceuticals for the treatment of symptoms associated with alcohol withdrawal, opioid use disorder; opioid withdrawal, substance abuse withdrawal, depression or other central nervous system disorders
PACIFILM	United Kingdom	Application No. 3501827 Registration No. 3501827	Class 05: Pharmaceuticals for the treatment of agitation; pharmaceuticals for the treatment of agitation associated with neuropsychiatric conditions, neurodegenerative diseases; alcohol withdrawal, opioid use disorder, opioid withdrawal, substance abuse withdrawal, or other central nervous system disorders

MARK	COUNTRY	APPLICATION/REGISTRATION NO.	GOODS/SERVICES
PACIFLM	United Kingdom	Application No. 18256423 Registration No. UK00918256423	Class 05: Pharmaceuticals for the treatment of agitation; pharmaceuticals for the treatment of agitation associated with neuropsychiatric conditions; neurodegenerative diseases; alcohol withdrawal opioid use disorder; opioid withdrawal, substance abuse withdrawal, or other central nervous system disorders
PACPEN	United Kingdom (via Madrid Protocol)	Application No. 1580863	Class 05: Injectable pharmaceutical preparations for the treatment of agitation; injectable pharmaceutical preparations for the treatment of agitation associated with neuropsychiatric conditions; neurodegenerative diseases; alcohol withdrawal, opioid use disorder; opioid withdrawal, substance abuse withdrawal and other related central nervous system disorders
RELFINBI	United Kingdom (via Madrid Protocol)	Application No. A0120399	Class 05: Pharmaceuticals for the treatment of central nervous system disorders; pharmaceuticals for the treatment of neurological and psychiatric disorders; pharmaceuticals for the treatment of agitation; pharmaceuticals for the treatment of agitation associated with neuropsychiatric conditions; neurodegenerative diseases; schizophrenia, bipolar disorder, dementia, delirium, alcohol withdrawal, opioid use disorder; opioid withdrawal, substance abuse withdrawal, depression or any other central nervous system disorder; pharmaceuticals for the treatment of symptoms associated with alcohol withdrawal, opioid use disorder; opioid withdrawal, substance abuse withdrawal, depression or other central nervous system disorders
ZELTGNA	United Kingdom (via Madrid Protocol)	Application No. A0120398	Class 05: Pharmaceuticals for the treatment of central nervous system disorders; pharmaceuticals for the treatment of neurological and psychiatric disorders; pharmaceuticals for the treatment of agitation; pharmaceuticals for the treatment of agitation associated with neuropsychiatric conditions; neurodegenerative diseases; schizophrenia, bipolar disorder, dementia, delirium, alcohol withdrawal, opioid use disorder; opioid withdrawal, substance abuse withdrawal, depression or any other central nervous system disorder; pharmaceuticals for the treatment of symptoms associated with alcohol withdrawal, opioid use disorder; opioid withdrawal, substance abuse withdrawal, depression or other central nervous system disorders

TRADEMARK

REEL: 007696 FRAME: 0372

RECORDED: 04/19/2022